Brokerages Set argenx SE (NASDAQ:ARGX) Target Price at $530.42

Shares of argenx SE (NASDAQ:ARGX) have been given a consensus recommendation of “Moderate Buy” by the twenty-one brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $530.74.

Several research analysts have recently commented on the stock. Robert W. Baird lowered their target price on shares of argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a report on Friday, March 1st. Scotiabank raised their target price on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a report on Tuesday. TD Cowen raised their target price on shares of argenx from $612.00 to $641.00 and gave the stock an “outperform” rating in a report on Tuesday, December 12th. HC Wainwright reissued a “buy” rating and issued a $451.00 price objective on shares of argenx in a research note on Wednesday. Finally, Raymond James decreased their price objective on shares of argenx from $580.00 to $520.00 and set a “strong-buy” rating on the stock in a research note on Thursday, December 21st.

argenx Stock Down 1.2 %

Shares of ARGX stock opened at $393.72 on Friday. The firm has a 50 day moving average price of $388.49 and a two-hundred day moving average price of $434.03. The company has a market capitalization of $23.35 billion, a PE ratio of -76.60 and a beta of 0.65. argenx has a 12-month low of $327.73 and a 12-month high of $550.76.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.45). argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. The company had revenue of $417.84 million for the quarter, compared to analyst estimates of $378.60 million. During the same quarter last year, the business earned ($0.70) earnings per share. As a group, research analysts expect that argenx will post -2.08 EPS for the current year.

Institutional Trading of argenx

A number of hedge funds have recently added to or reduced their stakes in ARGX. Capital World Investors boosted its position in argenx by 37.0% in the fourth quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after buying an additional 530,181 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of argenx by 339.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company’s stock worth $285,925,000 after purchasing an additional 449,151 shares during the period. Morgan Stanley lifted its holdings in shares of argenx by 236.9% during the fourth quarter. Morgan Stanley now owns 630,330 shares of the company’s stock worth $238,788,000 after purchasing an additional 443,217 shares during the period. Jennison Associates LLC lifted its holdings in shares of argenx by 32.2% during the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock worth $743,219,000 after purchasing an additional 368,367 shares during the period. Finally, Artisan Partners Limited Partnership lifted its holdings in shares of argenx by 12.2% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock worth $1,207,666,000 after purchasing an additional 346,178 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.